Breaking News
Home / Business News (page 20)

Business News

Abbott to Acquire Mitral Valve Device Maker Cephea Valve Technologies

ABBOTT PARK, Ill., Jan. 16, 2019 /PRNewswire/ — Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Financial terms were not disclosed. Abbott provided capital and secured …

Read More »

ZappRx and Bayer Partner to Improve Access to Specialty Medications

BOSTON–(BUSINESS WIRE)–ZappRx, a digital health company that streamlines the complex processes associated with prescribing specialty medications, announced an agreement with Bayer to provide a more efficient approach to the accessing of specialty medications and associated support programs. ZappRx will support patients living with two specific types of Pulmonary Hypertension (PH) and patients …

Read More »

Ferring Acquires Commercialization Rights for Two Products, Expanding its Reproductive Health Portfolio

PARSIPPANY, N.J.–(BUSINESS WIRE)–Ferring Pharmaceuticals (US) (Ferring) announced today an exclusive agreement to acquire the U.S. commercialization rights for a generic version of Ganirelix Acetate Injection from Sun Pharmaceutical Industries Ltd. (Sun Pharma). With the addition of Ganirelix, Ferring continues to offer the most complete reproductive medicine portfolio available, which includes …

Read More »

ASCO and Tempus Collaborate to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR) Study

ALEXANDRIA, Va. and CHICAGO, Jan. 10, 2019 (GLOBE NEWSWIRE) — The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating in ASCO’s Targeted Agent and Profiling Utilization (TAPUR™) Study. The TAPUR Study is a prospective, non-randomized clinical trial that aims to …

Read More »

Pfizer Collaborates with CytoReason To Utilize CytoReason’s Machine Learning Model of the Immune System for Drug Discovery

TEL AVIV, Israel–(BUSINESS WIRE)–CytoReason, a leader in machine learning for drug discovery and development, announced today that it has entered into a collaboration agreement with Pfizer Inc. (NYSE:PFE) that will leverage CytoReason’s cell-centered models of the immune system. CytoReason will receive from Pfizer payments potentially equaling up to low double …

Read More »

bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies

CAMBRIDGE, Mass. & SAN DIEGO–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Inhibrx, Inc. (Inhibrx) today announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Inhibrx’s proprietary single domain antibody (sdAb) platform to multiple cancer targets. The …

Read More »

Personal Genome Diagnostics and PathGroup Partner to Accelerate the Availability of Comprehensive Genomic Profiling with TMB

BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, and PathGroup, a premier provider of anatomic, clinical and molecular laboratory services, announced today that they have entered into a co-development agreement for the PGDx elio™ tissue complete assay. This collaboration brings together PGDx’s scientific, development and regulatory expertise …

Read More »

Lilly to Pay $8 Billion to Acquire Loxo Oncology

Eli Lilly and Company (NYSE: LLY) and Loxo Oncology, Inc. (NASDAQ: LOXO) today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be the …

Read More »

Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

PARIS and TARRYTOWN, NY – January 7, 2019 – Sanofi (EURONEXT: SAN, NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have restructured their global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. The 2015 Agreement was scheduled to end in approximately mid-2020, and this revision provides for ongoing collaborative development of two clinical-stage …

Read More »

QIAGEN Acquires N-of-One, Expanding Its Clinical Bioinformatics Capabilities in Molecular Oncology Decision Support

Redwood City, California, and Hilden, Germany, January 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The addition of N-of-One …

Read More »